InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
4,995.24
(
-0.32%
)
US TECH 100
16,722.40
(
-1.26%
)
Dow Jones
37,965.31
(
0.50%
)
Brent Oil
86.73
(
0.36%
)
Bitcoin
64,646.70
(
1.79%
)
Post# of 321
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

MZlu

Send PM Follow Ignore
Followers 4
Posts 21
Boards Moderated 0
Alias Born 01/25/2021

MZlu

Re: tootalljones post# 126

Monday, 05/24/2021 10:57:36 AM

Monday, May 24, 2021 10:57:36 AM

Post# of 321
It allows for a quicker approval process as the patients should be easier to recruit for phase 3 (inclusion criteria are more defined for Down Syndrom patients. Besides, they are a rather large population).

Annovis will also very probably get Orphan Drug designation.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent ANVS News
More ANVS News
InvestorsHub NewsWire

VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM

Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM

ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM

Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM

Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM

Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM

Start posting your company's news
Only $200 per official company press release!